Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Novartis AG (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
NVS
New York
2834
https://www.novartis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Novartis AG (ADR)
Techs boost STOXX to one-week high; euro zone data on tap
- Apr 23rd, 2024 7:01 am
Novartis Raises Guidance on Profit, Sales Growth
- Apr 23rd, 2024 5:31 am
UPDATE 4-Novartis raises guidance after beating Q1 expectations
- Apr 23rd, 2024 5:18 am
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
- Apr 23rd, 2024 5:00 am
Top Analyst Reports for Novartis, American Express & ConocoPhillips
- Apr 22nd, 2024 5:17 pm
Novartis (NVS) to Report Q1 Earnings: What to Expect?
- Apr 19th, 2024 2:10 pm
US FDA mandates label updates on CAR-T cancer therapies
- Apr 18th, 2024 10:33 pm
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
- Apr 18th, 2024 1:15 pm
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
- Apr 17th, 2024 1:30 pm
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
- Apr 17th, 2024 5:15 am
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
- Apr 16th, 2024 1:06 pm
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
- Apr 15th, 2024 6:00 pm
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
- Apr 15th, 2024 8:46 am
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
- Apr 12th, 2024 5:55 pm
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
- Apr 11th, 2024 8:19 pm
Novartis (NVS) to Undertake Job Cuts in Development Department
- Apr 11th, 2024 1:45 pm
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
- Apr 11th, 2024 11:40 am
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Apr 11th, 2024 11:00 am
UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys
- Apr 11th, 2024 8:39 am
Novartis tender offer for MorphoSys AG commences
- Apr 11th, 2024 8:20 am
Scroll